Rupert Handgretinger

Title: Rupert Handgretinger: Innovator in Immunosuppressive Therapy

Introduction

Rupert Handgretinger is a notable inventor based in Tübingen, Germany. He has made significant contributions to the field of immunosuppressive therapy through his innovative research and development of specific binding polypeptides.

Latest Patents

Handgretinger holds a patent titled "Methods for enhancing immunosuppressive therapy by multiple administration of αβTCR-binding polypeptide." This patent focuses on improved methods for utilizing a humanized binding polypeptide that is specific for the alpha beta T cell receptor (αβ-TCR). The disclosure emphasizes the use of a humanized anti-αβ-TCR antibody, derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. The methods described include the repetitive administration of humanized monoclonal antibodies and fragments to effectively reduce αβ T cells in subjects.

Career Highlights

Throughout his career, Handgretinger has worked with prominent organizations, including Genzyme Corporation and Eberhard Karls Universität Tübingen. His work has been instrumental in advancing therapeutic techniques that enhance patient outcomes in immunosuppressive treatments.

Collaborations

Handgretinger has collaborated with notable colleagues such as Gregor Blank and Karin Schilbach. These partnerships have contributed to the development of innovative solutions in the field of immunology.

Conclusion

Rupert Handgretinger is a distinguished inventor whose work in immunosuppressive therapy has paved the way for new treatment methodologies. His patent and collaborations reflect his commitment to advancing medical science and improving patient care.